
康沣生物-B公布,与认购人(LP Investment Holdings Group及郦军先生)订立认购协议,拟以每股5.36港元的价格向认购人发行合共746万股H股,该认购价较当日收市价折让约17.79%。此次认购所得净额约3973万港元,其中80%将用于血管、呼吸及肿瘤介入相关的微创介入产品的研发、生产、商业化及潜在海外业务扩张,剩余20%将用作集团一般营运资金。
“特别声明:以上作品内容(包括在内的视频、图片或音频)为凤凰网旗下自媒体平台“大风号”用户上传并发布,本平台仅提供信息存储空间服务。
Notice: The content above (including the videos, pictures and audios if any) is uploaded and posted by the user of Dafeng Hao, which is a social media platform and merely provides information storage space services.”